Are open-source patent portfolios the key to the EV revolution?

No items found.
​
June 16, 2022

The widespread rollout of electric vehicles is viewed as a crucial part of the UK's green revolution. When discussing how this can be achieved, charging infrastructure is often cited as the key to ensuring the appeal and accessibility of electric vehicles to the mass consumer market. This was highlighted by Boris Johnson's announcement in November of last year, where he declared the "electric vehicle revolution", which would involve installing 145,000 extra charge points by 2030. The argument is that the wider availability of charging points would increase consumer certainty, and thus increase the demand for electric vehicles. Inevitably, such confidence in the market would lead to a greater stream of innovators wanting their share of it.

However, the impact of "open-source" patent portfolios in accelerating the EV industry has often been overlooked. With both Tesla and Toyota taking the decision to open-source their patents respectively, they claimed the decision was made to remove barriers, spark greater innovation within the electric vehicle industry and ultimately open up the road to sustainability. This article will examine the actions these companies have taken, the impact they have had and ultimately, whether open-source patent portfolios are the key to driving the greater expansion of the industry.

What are open-source patents?

Open-Source patents are a method of combining traditional patents and open-source models.

A patent is a type of intellectual property that gives its owner the legal right to exclude others from making, using, or selling an invention for a limited period of time in exchange for publishing an enabling disclosure of the invention. By deciding to open-source patents, the patent owners are ostensibly allowing third parties to use such patented technologies at no cost. Depending upon the terms on which the patentees choose to "open-source" their patent rights (of which more later), the patentees will have made a commitment not to sue any people working the patented inventions and third parties therefore won't be in danger of any legal proceeding. The move is often driven by the desire for greater collaboration between companies to develop future technology at speed.

Tesla and Toyota

In the now famous blog post, Elon Musk announced in 2014 "All Our Patent Are Belong To You". He explained the decision was made in the spirit of innovation within the industry and the advancement of electric vehicle technology, through removing the roadblocks of intellectual property.

Five years later, Toyota similarly announced that it would allow other companies to use nearly 24,000 patents related to its hybrid car technology, which would be available to license for royalty-free use until 2030, and Toyota will also offer consultation services for a fee. Again, this was motivated by increasing the speed of the transition from fossil fuelled cars to electric vehicles.

The actions by top brands and innovators within the industry have two significant implications, in theory. To those looking to enter the market, being able to borrow from the industry-leading technology that both Toyota and Tesla have developed has the potential to provide a head start to research and development, providing an initial foundation to work from. In turn, by helping potential competitors Toyota and Tesla are speeding up the process of innovation, and increasing consumer choice, which should have long term benefits to the buyer.

Therefore, in theory, the "open-source" patent pledges are incredibly useful for new businesses looking to enter the electric vehicle market. However, those who are looking to take Toyota or Tesla up on the offers must make some important considerations before doing so.

As simple as it seems?

From a glance, such moves from Tesla and Toyota significantly simplify the patent process. However, upon closer investigation of the conditions attached, to the extent that those conditions are publicly available, it is possible that they render these pledges "open-source" in name only.

For Tesla, the Patent Pledge states that the company "will not initiate a lawsuit against any party for infringing a Tesla Patent through activity relating to electric vehicles or related equipment for so long as such party is acting in good faith." In explanation of this point, it explains that a party is not acting in good faith if they:

·asserted, helped others assert, or had a financial stake in any assertion of (i) any patent or other intellectual property right against Tesla or (ii) any patent right against a third party for its use of technologies relating to electric vehicles or related equipment;

·challenged, helped others challenge, or had a financial stake in any challenge to any Tesla patent; or

·marketed or sold any knock-off product (e.g., a product created by imitating or copying the design or appearance of a Tesla product or which suggests an association with or endorsement by Tesla) or provided any material assistance to another party doing so.

The first point illustrates the substantial risk that could come to companies who choose to take Tesla up on their Patent Pledge offer. The condition could stop any party that's using Tesla's patents from suing Tesla for any suspected infringement of their own IP rights (and not just patents). Similarly, the use of the colloquial term "knock-off" could leave companies vulnerable to future litigation, meaning a company using Tesla's patented technology must be careful in the product design to ensure that Tesla cannot suggest it is a knock-off. Thus, some would say that Tesla's conditions illustrate they have not given away any of his company's patents "for free". Rather, they gave up some rights to enforce them, and in return expected the same from their competitors.

To find out the details of Toyota's conditions, those interested must contact the company directly to discuss specific licensing terms and conditions. Thus, it is difficult to make any judgements on their offer.

Conclusion

Whilst there are clear PR benefits, it is hard to judge the real impact of Toyota and Tesla's decisions – but, accelerating the growth of the electric vehicle industry certainly seems to be their aim.

However, despite Tesla making the announcement eight years ago, there has been speculation that there is actually little evidence that any major automakers have used the technology the company developed. Furthermore, while Toyota followed a similar path, the fact that other dominant players in the industry have not followed suit would suggest that is unlikely to become a wider trend in the industry.

A clear takeaway from Tesla's pledge is that companies who may wish to use similar open-source opportunities in the future must be careful to consider the small print, and the potential implications for the protection of their own technological developments in the future.

This article was first published in Automotive World.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​